
About Kuros Biosciences
Kuros Biosciences is a publicly listed company based in Schlieren (Switzerland) founded in 2000. Provider of smart solutions for bone disease management. Kuros Biosciences has raised $24.65 million across 7 funding rounds from investors including Optiver, European Union and Life Sciences Partners. The company has 4 employees. Kuros Biosciences has completed 1 acquisition, including Xpand Biotechnology. Its website kurosbio.com draws about 12 thousand monthly visits. Kuros Biosciences offers products and services including MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is Kuros Biosciences AG.
Company details
Kuros Bioscience is a provider of smart solutions for bone disease management. It has developed solutions to improve patient rehabilitation. It provides a MagnetOs, a unique bone graft with submicron surface topography, that harnesses the power of osteoimmunology to deliver uniform, solid and stable spinal fusions. It has also developed a Fibrin-PTH candidate that delivers targeted and controlled bone formation. It promotes bone formation through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The device is in clinical trial 2A stage FDA approved.
- Headquarters Schlieren, Switzerland
- Employees 4
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website kurosbio.com
- Social LinkedIn Facebook Instagram YouTube
- Legal Name Kuros Biosciences Ltd.
- Annual Revenue$153.03 M (USD)61.74as on Dec 31, 2025
- Net Profit$2.67 M (USD)as on Dec 31, 2025
- EBITDA$12.78 M (USD)288.78as on Dec 31, 2025
- Total Equity Funding$24.65M (USD)
in 7 rounds
- Latest Funding Round$6.24M (USD), Post-IPO
Sep 2022
- InvestorsOptiver
& 11 more
- Employee Count4
- Investments & Acquisitions
Products & Services of Kuros Biosciences
Kuros Biosciences offers a comprehensive portfolio of products and services, including MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules.
Promotes bone growth for spinal fusions using advanced surface technology.
Provides flexible bone graft solution for surgical applications.
Enables predictable fusion in spinal procedures.
Supports bone regeneration in soft tissue environments.
Facilitates bone growth for fusion surgeries.
Apps and channels of Kuros Biosciences
its YouTube channel Kuros Biosciences has 215 subscribers and 30 videos.
Videos from Kuros Biosciences
The most watched videos on Kuros Biosciences's YouTube channel, Kuros Biosciences (215 subscribers). Click a video to play it here.
More on Kuros Biosciences.
Funding Insights of Kuros Biosciences
Kuros Biosciences has successfully raised a total of $24.65M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.24 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.65M
- Total Rounds 7
- Last Round Post-IPO β $6.24M
- First Round $4.32M
(Oct 2005)
- Investors Count 12
All 7 funding rounds of Kuros Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $6.24M | Post-IPO | β | β | |
| Jan 2021 | $490,543 | Grant | β | β | |
| Jan 2020 | $488,179 | Grant | β | β | |
| Jan 2019 | $16M | Post-IPO | β | β | β |
| Nov 2015 | $4.97M | Series B | β | β | β |
| Aug 2015 | $15.35M | Series B | β | LifeCare Partners | |
| Oct 2005 | $4.32M | Series A | β | NeoMed, DEFI Gestion |
12 investors in total: 12 institutional.
Investors in Kuros Biosciences
Kuros Biosciences has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Optiver, European Union and Life Sciences Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
LifeCare Partners is involved in unspecified activities. | lifecare.partners | |||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Early-stage venture capital is invested in US and Europe. | vipartners.ch | Altendorf, Switzerland | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
Stage-agnostic life sciences-focused VC firm investing in North America & Europe | neomed.net | Oslo, Norway | ||
| defigestion.ch | ||||
Market-making services for financial instruments are provided globally. | 1986 | optiver.com | Amsterdam, Netherlands | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Investments are made in Swiss SMEs for succession and growth. | 1997 | renaissance.net | Lausanne, Switzerland | |
B2B portal for client imports, product management, and user account handling. | 1988 | cdcentreprises.fr | Paris, France |
Investor details for Kuros Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Kuros Biosciences
Kuros Biosciences is a publicly listed company on the SIX with ticker symbol KURN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Aug 2018
- Listed onCSE: SPEY
- Listed entityKuros Biosciences Ltd.
- Exchange sectorHealth technology
- ISINCH0325814116
- Share price20.00 CHF (-0.6% on the day) · 2026-05-11
- Market capitalisation792,969,064.00 CHF
- Price to earnings434.8
- EPS (diluted, trailing year)0.05 CHF
- Volume (last session)48,700
- Analyst consensusStrong buy
Financials of Kuros Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 121.3M CHF | 2.1M CHF | 10.1M CHF |
| 2024 | 75.0M CHF | -4.3M CHF | 2.6M CHF |
| 2023 | 33.6M CHF | -13.7M CHF | -2.6M CHF |
| 2022 | 18.0M CHF | -14.6M CHF | -7.4M CHF |
| 2021 | 13.8M CHF | -7.5M CHF | -6.1M CHF |
Detailed financial statements for Kuros Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kuros Biosciences
Kuros Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Xpand Biotechnology.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Mini-bioreactors are developed as alternatives to 2D cell culture systems. | xpand-biotech.com | Bilthoven, Netherlands | 2004 | Dec 2016 | $29M |
Complete acquisition details for Kuros Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Kuros Biosciences
5 dated milestones of Kuros Biosciences across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Kuros Biosciences is founded.
- Funding First funding round of $4.3M.
- Acquisition Acquires Xpand Biotechnology.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $6.2M.
Web traffic of Kuros Biosciences
The website of Kuros Biosciences (kurosbio.com) receives about 12.1K visits a month.
- Monthly visits12.1K
▲ 37% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kuros Biosciences
Complete news archive for Kuros Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kuros Biosciences
Kuros Biosciences was founded in 2000 and raised its 1st funding round 5 years after it was founded.
Kuros Biosciences is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Kuros Biosciences is a funded company, having raised a total of $24.65M across 7 funding rounds to date. The company's 1st funding round was a Series A of $4.32M, raised on Oct 2005.
Kuros Biosciences has 4 employees.
Annual revenue of Kuros Biosciences is $153.03M as on Dec 31, 2025.
Kuros Bioscience is a provider of smart solutions for bone disease management. It has developed solutions to improve patient rehabilitation. It provides a MagnetOs, a unique bone graft with submicron surface topography, that harnesses the power of osteoimmunology to deliver uniform, solid and stable spinal fusions. It has also developed a Fibrin-PTH candidate that delivers targeted and controlled bone formation. It promotes bone formation through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The device is in clinical trial 2A stage FDA approved.
Kuros Biosciences offers MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules.
Yes, Kuros Biosciences is publicly traded on SIX under the ticker symbol KURN.
Kuros Biosciences has made 1 acquisition, including Xpand Biotechnology.
Kuros Biosciences has 12 investors. Key investors include Optiver, European Union, Life Sciences Partners, LifeCare Partners, and VIP Partners.
Kuros Biosciences operates through Kuros Biosciences Ag.
